ArticleBMC cancer2026
Effect of body mass index and age on the prognosis of non-metastatic nasopharyngeal carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeGiven the critical roles of body mass index (BMI) and age in cancer prognosis, this study investigated their impact on non-metastatic nasopharyngeal carcinoma (NPC).
methodsPatients aged > 18 years with newly diagnosed non-metastatic NPC treated at the First Affiliated Hospital of Guangxi Medical University between June 2016 and March 2020 were retrospectively enrolled. BMI at diagnosis was classified into underweight, normal, overweight, and obese categories according to the WHO Asian BMI criteria, and patients were stratified into 20-year age intervals.
resultsA total of 674 patients were included in the study. There were 310 (46.0%), 244 (36.2%), 45 (6.7%), and 75 (11.1%) patients in the normal, overweight, obese, and underweight BMI groups, respectively. Age distribution was 205 (30.4%) young, 393 (58.3%) middle-aged, and 76 (11.3%) older. The median follow-up duration was 72 months (range, 3-98 months). The 5-year overall survival (OS) and event-free survival (EFS) rates were 79.2% and 77.0%, respectively. Overweight patients had significantly better OS than those with normal BMI (85.2% vs. 77.4%, p = 0.021) or underweight BMI (85.2% vs. 69.3%, p < 0.001). Underweight patients had a worse EFS than overweight (66.7% vs. 81.6%, p = 0.002) or normal patients (66.7% vs. 76.8%, p = 0.029). Survival outcomes declined with age (p < 0.05). Cox multivariate analysis identified underweight BMI and advanced age as independent adverse prognostic factors (p < 0.05).
conclusionUnderweight BMI and advanced age at diagnosis are associated with poor prognosis in non-metastatic NPC. These findings confirm previous observations in a modern IMRT-treated cohort and emphasize that these associations are hypothesis-generating, without implying direct causal effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.